Neurizon executes long-term supply agreement with Elanco
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This milestone supports Neurizon's strategic positioning as a clinically advanced company focused on neurodegenerative diseases. The agreement includes an initial five-year term and provisions for production scheduling and confidentiality.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
- HEALEY ALS Platform Trial Regimen I expands to 240 participants
- HEALEY ALS Trial Regimen I Expands to 240 Participants
- Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
- Placement of Entitlement Offer Shortfall
Later from Neurizon Therapeutics
- HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
- Melbourne investor briefing presentation
- Appendix 4C & Quarterly Update
- Neurizon Enters Strategic R&D Financing Facility
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics